Impiego delle tecniche di imaging nelle demenze - Istituto Superiore ...

Impiego delle tecniche di imaging nelle demenze
20. Galton CJ, Erzinçlioglu S et al. A comparison
of the Addenbrooks’s Cognitive Examination
(ACE), conventional neuropsychological assessment,
and simple MRI-based medial temporal
lobe evaluation in the early diagnosis of Alzheimer’s
disease. Cogn Behav Neurol
2005;18(3):144-50.
21. Adak S, Illouz K et al. Predicting the rate of
cognitive decline in aging and early Alzheimer
disease. Neurology 2004;63(1):108-14.
22. Sluimer JD, Vrenken H et al. Whole-brain
atrophy rate in Alzheimer disease. Identifying
fast progressors. Neurology 2008;70(19 Pt
2):1836-41.
23. Teipel SJ, Bayer W et al. Progression of corpus
callosum atrophy in Alzheimer disease. Arch
Neurol 2002;59(2):243-8.
24. Waldman AD, Rai GS. The relationship
between cognitive impairment and in vivo metabolite
ratios in patients with clinical Alzheimer’s
disease and vascular dementia: a proton magnetic
resonance spectroscopy study. Neuroradiology
2003;45(8):507-12.
25. Holtmanspotter M, Peters N et al. Diffusion
magnetic resonance histograms as a surrogate
marker and predictor of disease progression in
Cadasil: a two-year follow-up study. Stroke
2005;36(12):2559-65.
26. Liem MK, Lesnik Oberstein SA et al. Cerebral
autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy: progression
of mr abnormalities in prospective
7-year follow-up study. Radiology
2008;249(3):964-71.
27. Molko N, Pappata S et al. Monitoring disease
progression in Cadasil with diffusion magnetic
resonance imaging. a study with whole brain
histogram analysis. Stroke 2002;33(12):2902-8.
28. Drzezga A, Grimmer T et al. Prediction of
individual clinical outcome in MCI by means of
genetic assessment and sup18F-FDG PET. J
Nucl Med 2005;46(10):1625-32.
29. Mosconi L, Perani D et al. MCI conversion
to dementia and the APOE genotype. Neurology
2004;63(12):2332-40.
30. Anchisi D, Borroni B et al. Heterogeneity of
brain glucose metabolism in MCI and Clinical
progression to AD Arch Neurol 2005;62(11):
1728-33.
31. Chetelat G, Desgranges B et al. Mild cognitive
impairment. Can FDG-PET predict who is
to rapidly convert to Alzheimer’s disease? Neurology
2003;60(8):1374-7.
32. Silverman DH, Truong CT et al. Prognostic
value of regional cerebral metabolism in patients
undergoing dementia evaluation: comparison to
a quantifying parameter of subsequent cognitive
performance and to prognostic assessment without
PET. Mol Genet Metab 2003;80(3):
350-5.
33. Borroni B, Anchisi D e al. Combined 99mTc-
ECD SPECT and neuropsychological studies in
MCI for the assessment of conversion to AD.
Neurobiol Aging 2006;27(1):24-31.
34. Encinas M, De Juan R et al. Regional cerebral
blood flow assessed with 99mTc-ECD
SPET as a marker of progression of mild cognitive
impairment to Alzheimer’s disease. Eur J
Nucl Med Mol Imaging 2003;30(11):1473-80.
35. Gabrielewicz T, Pawłowska-Detko A et al.
Prediction of deterioration of mild cognitive impairment
with CT and SPECT. Med Sci Monit
2007;13 (Suppl 1):31-7.
36. Huang C, Wahlund LO et al. Cingulate cortex
hypoperfusion predicts Alzheimer’s disease in
mild cognitive impairment. BMC Neurol
2002;2:9.
37. Ishiwata A, Sakayori O et al. Preclinical evidence
of Alzheimer changes in progressive mild
cognitive impairment: a qualitative and quantitative
SPECT study. Acta Neurol Scand
2006;114(2):91-6.
38. Okamura N, Arai H et al. Combined analysis
of CSF Tau levels and [123I]Iodoamphetamine
SPECT in mild cognitive impairment: implications
for a novel predictor of Alzheimer’s di-
56 Quesiti e raccomandazioni